The US Food and Drug Administration expanded the authorized use of Pfizer Inc. and BioNTech SE’s COVID-19 vaccine to adolescents on 10 May, just hours after announcing plans for a June advisory committee meeting to discuss pediatric data requirements for vaccines directed against the SARS-CoV-2 virus.
The FDA granted Pfizer’s request to expand the vaccine’s emergency use authorization to include individuals ages 12-15 years old, making...







